Next 10 |
home / stock / snynf / snynf news
2024-05-02 07:55:40 ET More on Regeneron Pharmaceuticals Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript) Regeneron Pharmaceuticals, Inc. (REGN) Barclays ...
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus n...
2024-05-01 14:27:40 ET Summary Sanofi acquired Inbrx to add lung disorders to its treatment portfolio, with an estimated sales peak of €600 million by 2032. The company settled 4,000 lawsuits related to Zantac, which is not expected to impact its balance sheet significantly...
Annual General Meeting of April 30, 2024 Approval of the financial statements for the fiscal year 2023 Distribution of a cash dividend of €3.76 per share, with payment as of May 15, 2024 Board composition: renewal of two Directors and appointment of three new Independent Di...
2024-04-30 11:30:18 ET Summary Sanofi beat Q1 earnings estimates with revenue at $11.36 billion and EPS at 97 cents, driven largely by Dupixent. Key drugs like Nexviazyme and Altuviiio showed strong performance, with the former doubling its revenue. Despite a high profitabilit...
2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...
2024-04-25 11:24:10 ET Sanofi (SNY) Q1 2024 Earnings Conference Call April 25, 2024 08:30 AM ET Company Participants Paul Hudson - Chief Executive Officer François-Xavier Roger - Chief Financial Officer Houman Ashrafian - Executive Vice President & Head-...
2024-04-25 01:38:35 ET More on Sanofi: Sanofi: My Top Pick In Big Pharma Sanofi reportedly lining up banks for consumer products spinoff Sanofi succeeds in late-stage trial for blood disorder candidate Read the full article on Seeking Alpha For furthe...
Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS (1) of €1.78 Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€...
2024-04-23 09:44:51 ET More on Sanofi Sanofi: My Top Pick In Big Pharma Sanofi (SNY) Barclays 26th Annual Global Healthcare Conference (Transcript) Sanofi (SNY) Leerink Partners Global Biopharma Conference (Transcript) Sanofi reportedly settles 4K Zantac case...
News, Short Squeeze, Breakout and More Instantly...
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus n...
Annual General Meeting of April 30, 2024 Approval of the financial statements for the fiscal year 2023 Distribution of a cash dividend of €3.76 per share, with payment as of May 15, 2024 Board composition: renewal of two Directors and appointment of three new Independent Di...
Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS (1) of €1.78 Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€...